Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Curevo Raises $110 Million with Support from Medicxi and Other Investors to Advance Amezosvatein Shingles Vaccine

Mar 17, 2025•about 1 year ago

Contract Type

partnership

BothellBiotechnologyMobileSportsPlatforms

Description

Curevo Vaccine has announced the closing of a $110 million Series B round to advance the development of their shingles vaccine, amezosvatein, following successful Phase 2 study results. The round was led by new investor Medicxi and joined by other international investment funds.

Company Information

Company

Curevo

Location

Bothell, Washington, United States

About

Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Curevo's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months